Veracyte Inc
NASDAQ:VCYT

Watchlist Manager
Veracyte Inc Logo
Veracyte Inc
NASDAQ:VCYT
Watchlist
Price: 42.17 USD 2.6% Market Closed
Market Cap: 3.3B USD
Have any thoughts about
Veracyte Inc?
Write Note

Veracyte Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Veracyte Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Veracyte Inc
NASDAQ:VCYT
Pre-Tax Income
-$8.2m
CAGR 3-Years
53%
CAGR 5-Years
0%
CAGR 10-Years
11%
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$7.2B
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$176m
CAGR 3-Years
-73%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$4.7B
CAGR 3-Years
-10%
CAGR 5-Years
-13%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$259.6m
CAGR 3-Years
-54%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5B
CAGR 3-Years
-15%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Veracyte Inc
Glance View

Market Cap
3.3B USD
Industry
Biotechnology

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 761 full-time employees. The company went IPO on 2013-10-30. The firm offers customized biomarker testing and analytical services. The company offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. The company offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. The company also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.

VCYT Intrinsic Value
17.31 USD
Overvaluation 59%
Intrinsic Value
Price

See Also

What is Veracyte Inc's Pre-Tax Income?
Pre-Tax Income
-8.2m USD

Based on the financial report for Sep 30, 2024, Veracyte Inc's Pre-Tax Income amounts to -8.2m USD.

What is Veracyte Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
11%

Over the last year, the Pre-Tax Income growth was 84%. The average annual Pre-Tax Income growth rates for Veracyte Inc have been 53% over the past three years , and 11% over the past ten years .

Back to Top